Further studies will be required to better understand the relationship between oxylipins with cognitive decline and other complications in people with T2DM and whether the CYP450-sEH pathway may serve as a potential therapeutic target to prevent worsening of cognitive symptoms and subsequent conversion to dementia. This evidence concerns the gene EPHX2 and dementia.